Ralph Snyderman

From Wikipedia, the free encyclopedia
Ralph Snyderman
Ralph Snyderman.jpg
Born (1940-03-13) March 13, 1940 (age 81)
Brooklyn, NY[1]
EducationB.S. Washington College, Chestertown, MD (1961) M.D. State University of New York, Downstate Medical Center (1965)
TitleChancellor Emeritus, Duke University;

James B. Duke Professor of Medicine, Duke University School of Medicine;

Executive Director, Duke Center for Personalized Health Care
Board member ofCareDx

iRhythm Technologies

Liquidia Technologies

Washington College Board of Visitors and Governors

Ralph Snyderman is chancellor emeritus at Duke University, James B. Duke Professor of Medicine, and executive director of the Duke Center for Personalized Health Care.[2][3] He served as chancellor for health affairs and dean of the School of Medicine from 1989 to July 2004.[4] Under his leadership, Duke University created the Duke University Health System (DUHS) to develop and operate a comprehensive health delivery system, and he was its founding President and Chief Executive Officer. DUHS, with its practice networks, ambulatory care centers, home health services, community hospitals, university hospital, and satellite collaborations demonstrated the power of academic medicine to deliver the best of care to broad communities.[5] Snyderman helped lead the creation of the Duke Clinical Research Institute, the largest academic clinical research organization worldwide.[3] During his tenure, Duke University Hospital was ranked 6th overall in the nation and its medical school ranked 4th.[6] Snyderman is a leader in the conception and development of personalized health care, an evolving model of national health care delivery.[7] He has articulated the need to move the current focus of health care from the treatment of disease-events to personalized, predictive, preventive, and participatory care that is focused on the patient.[8][9][10][11][12] Ralph Snyderman was the recipient of the 2012 David E. Rogers Award from the Association of American Medical Colleges who recognized him as "The Father of Personalized Medicine."[13] He is a member of the Association of American Medical Colleges (chair 2002-2003[14]), Association of American Physicians (President 2003-2004), American Academy of Arts & Sciences,[15] and the National Academy of Medicine.[16]

Early life and education[]

Snyderman was born on March 13, 1940 in Brooklyn, New York, the son of Russian immigrants Morris and Ida Snyderman.[2]  A graduate of Washington College in Chestertown, Maryland,[17] Snyderman received his MD in 1965 from SUNY Downstate Medical Center.[18][19] He served his internship and residency in medicine at Duke and later worked as a Public Health Officer doing research in immunology at the NIH.[20]

Career[]

Snyderman accepted his first faculty appointment at Duke in 1972 and by 1984, he was the Frederic M. Hanes Professor of Medicine and Immunology and chief of the Division of Rheumatology and Immunology. [19] His research contributed to the understanding of how white blood cells respond to chemical signals to mediate host defense or tissue damage. He is internationally recognized for his contributions in inflammation research.  In 1987, Snyderman left Duke to join Genentech, Inc., the pioneering biomedical technology firm, as Senior Vice President for medical research and development. While at Genentech, he led the development and licensing of major biotechnology therapeutics.  He returned to Duke in 1989 as Chancellor for Health Affairs, Duke University, a position he held until 2004.[21] Since then, Snyderman established and leads the Duke Center for Personalized Health Care which provides a platform for research directed at developing new models of care. Snyderman has served on numerous corporate boards of directors, including that of Purdue Pharma. He was named as a defendant in the Massachusetts Attorney General's complaint against the company in 2019[22] in connection with his board membership from 2012 through 2017. Purdue Pharma pleaded guilty 3 felonies covering the period between 2007 and 2017.[23]

Research[]

Snyderman’s research focused on defining the mechanisms by which leukocytes accumulate at sites of inflammation.  He developed the first reliable in vitro technology to quantify leukocyte chemotaxis.  His work led to the standard methodology to study this critical component of inflammation.  He identified C5a, a cleavage product of the fifth component of complement (C), as a major chemotactic factor which was produced by C activation or by proteolytic cleavage of C5.[24]  Snyderman’s work helped open the field of inflammation research to  scientific analysis and lay the foundation of our current understanding of leukocyte activation by chemoattractants and chemokine production by activated mononuclear cells.[25][26][27][28][29]

Snyderman’s current work is focused on the development and implementation of Personalized Health Care – a personalized, predictive, preventive, and participatory approach to care. This concept is facilitating the transformation of health care from the current disease-oriented approach to one that focuses on personalized health planning and is increasingly seen as a solution to our national health care dilemma.[7][8][9][12] The Duke Center for Personalized Health Care fosters the adoption of proactive, personalized, and patient-driven care into clinical practice, develops and tests novel clinical approaches to deliver personalized health care and functions as a think tank to foster innovation in health care delivery.[11][30] The center is currently working on multiple projects to study the feasibility and clinical outcomes of integrating personalized health care into ongoing clinical settings.

Snyderman has contributed to over 400 scientific manuscripts.[31]

Honors and awards[]

  • 1978   McLaughlin Award for Inflammation Research[32]
  • 1985   Humboldt Senior Scientist Award, Federal Republic of Germany[32]
  • 1992   Ciba-Geigy Morris Ziff Award, for lifetime achievements in inflammation research[32]
  • 1993   Bonazinga Award for Excellence in Leukocyte Biology Research[33]
  • 2003 Ellis Island Medal of Honor [34]
  • 2003 Bravewell Leadership Award[35]
  • 2007 Leadership in Personalized Medicine Award from the Personalized Medicine Coalition[36]
  • 2008 Industrial Research Institute (IRI) Medal[37]
  • 2008 Frost & Sullivan's 2008 North American HealthCare Lifetime Achievement Award[38]
  • 2010 Bioscience Leader Emeriti by the North Carolina Association for Biomedical Research[39]
  • 2011 William B. Anlyan, MD, Lifetime Achievement Award[40]
  • 2012 David E. Rogers Award from the Association of American Medical Colleges[13]
  • 2014 North Carolina Life Sciences Leadership Award[41]
  • 2016 Personalized Medicine World Conference's Pioneer Award[42]

References[]

  1. ^ "Ralph Snyderman in the 1940 Census | Ancestry®".
  2. ^ Jump up to: a b "People – Duke Personalized Health Care". Retrieved 2016-06-29.
  3. ^ Jump up to: a b "A Chancellor′s Tale | Duke University Press". www.dukeupress.edu. Retrieved 2016-06-30.
  4. ^ "Ralph Snyderman, Chancellor | Duke Medical Center Archives". archives.mc.duke.edu. Retrieved 2016-06-16.
  5. ^ Snyderman, Ralph (March 26, 2003). "The Chancellor's Journey". Duke Today. Retrieved April 22, 2020.
  6. ^ Snyderman, Ralph (April 14, 2004). "Duke Medical Ranked Fourth in US News & World Report". Retrieved April 21, 2020.
  7. ^ Jump up to: a b Williams, R. Sanders; Willard, Huntington F.; Snyderman, Ralph (2003-04-25). "Personalized Health Planning". Science. 300 (5619): 549. doi:10.1126/science.300.5619.549. PMID 12714710.
  8. ^ Jump up to: a b Snyderman, Ralph; Langheier, Jason (2006-01-01). "Prospective health care: the second transformation of medicine". Genome Biology. 7 (2): 104. doi:10.1186/gb-2006-7-2-104. PMC 1431721. PMID 16522218.
  9. ^ Jump up to: a b Snyderman, Ralph; Williams, R. Sanders (2003-11-01). "Prospective medicine: the next health care transformation". Academic Medicine. 78 (11): 1079–1084. doi:10.1097/00001888-200311000-00002. PMID 14604864.
  10. ^ Snyderman R; Weil AT (2002-02-25). "Integrative medicine: Bringing medicine back to its roots". Archives of Internal Medicine. 162 (4): 395–397. doi:10.1001/archinte.162.4.395. PMID 11863470.
  11. ^ Jump up to: a b R, Simmons LA, Drake CD, Gaudet TW, Snyderman. "Personalized Health Planning in Primary Care Settings : Federal Practitioner". www.fedprac.com. Retrieved 2016-06-29.
  12. ^ Jump up to: a b Snyderman, Ralph (August 2012). "Personalized health care: From theory to practice". Biotechnology Journal. 7 (8): 973–79. doi:10.1002/biot.201100297. PMID 22180345. S2CID 31447416 – via Wiley.
  13. ^ Jump up to: a b "2012 David E. Rogers Award – AAMC Awards – Initiatives – AAMC". www.aamc.org. Retrieved 2016-06-16.
  14. ^ Snyderman, Ralph (November 3, 2001). "Dr. Ralph Snyderman Named Chair of American Association of Medical Colleges". Duke Health. Retrieved April 8, 2020.
  15. ^ Snyderman, Ralph. "Ralph Snyderman - Member of AAAS". Duke Med. Retrieved April 21, 2020.
  16. ^ "Ralph Snyderman, M.D." National Academy of Medicine. Retrieved 29 June 2016.
  17. ^ Snyderman, Ralph. "Ralph Snydermam, MD Alumni". Washington College. Retrieved April 20, 2020.
  18. ^ Snyderman, Ralph. "SUNY Downstate Sesquicentennial". Downstate.edu. Retrieved April 20, 2020.
  19. ^ Jump up to: a b "Previous Chancellors – Duke Medicine". corporate.dukemedicine.org. Retrieved 2016-06-30.
  20. ^ https://nccih.nih.gov/training/videolectures/7/0
  21. ^ Snyderman, Ralph. "Ralph Snyderman Profile". Retrieved April 20, 2020.
  22. ^ https://www.mass.gov/doc/january-31-2019-first-amended-complaint-file-ref-nbr-43/download. Retrieved August 22, 2021. Missing or empty |title= (help)
  23. ^ "Opioid Manufacturer Purdue Pharma Pleads Guilty to Fraud and Kickback Conspiracies". 24 November 2020. Retrieved August 22, 2021.
  24. ^ Williams, L T; Snyderman, R; Pike, M C; Lefkowitz, R J (1977-03-01). "Specific receptor sites for chemotactic peptides on human polymorphonuclear leukocytes". Proceedings of the National Academy of Sciences of the United States of America. 74 (3): 1204–1208. Bibcode:1977PNAS...74.1204W. doi:10.1073/pnas.74.3.1204. PMC 430651. PMID 265563.
  25. ^ Shin, Hyun S.; Snyderman, Ralph; Friedman, Eileen; Mellors, Alice; Mayer, Manfred M. (1968-10-18). "Chemotactic and Anaphylatoxic Fragment Cleaved from the Fifth Component of Guinea Pig Complement". Science. 162 (3851): 361–363. Bibcode:1968Sci...162..361S. doi:10.1126/science.162.3851.361. PMID 4175690. S2CID 11800780.
  26. ^ Sbarra, Anthony J. (2013-11-11). Biochemistry and Metabolism. Springer Science & Business Media. ISBN 9781461591344.
  27. ^ Williams, L. T.; Snyderman, R.; Lefkowitz, R. J. (1976-01-01). "Identification of beta-adrenergic receptors in human lymphocytes by (-) (3H) alprenolol binding". The Journal of Clinical Investigation. 57 (1): 149–155. doi:10.1172/JCI108254. PMC 436634. PMID 1245597.
  28. ^ Snyderman, Ralph; Phillips, Jean; Mergenhagen, Stephan E. (1970-06-01). "Polymorphonuclear Leukocyte Chemotactic Activity in Rabbit Serum and Guinea Pig Serum Treated with Immune Complexes: Evidence for C5a as the Major Chemotactic Factor". Infection and Immunity. 1 (6): 521–525. doi:10.1128/IAI.1.6.521-525.1970. PMC 415936. PMID 16557770.
  29. ^ Snyderman, R.; Goetzl, E. J. (1981-08-21). "Molecular and cellular mechanisms of leukocyte chemotaxis". Science. 213 (4510): 830–837. Bibcode:1981Sci...213..830S. doi:10.1126/science.6266014. PMID 6266014.
  30. ^ Snyderman, Ralph (February 5, 2017). "To Adopt Precision Medicine, Redesign Clinical Care". NEJM Catalyst. doi:10.1056/CAT.17.0539 (inactive 2021-05-29). Retrieved April 20, 2020.CS1 maint: DOI inactive as of May 2021 (link)
  31. ^ pubmeddev. "Snyderman R – PubMed – NCBI". www.ncbi.nlm.nih.gov. Retrieved 2016-06-28.
  32. ^ Jump up to: a b c "Guide to Ralph Snyderman Papers". Retrieved April 21, 2020.
  33. ^ Snyderman, Ralph. "SLB Legacy Keynote Lecture Award". Retrieved April 21, 2020.
  34. ^ "Congressional Record – 108th Congress (2003-2004) – THOMAS (Library of Congress)". thomas.loc.gov. Retrieved 2016-06-28.[permanent dead link]
  35. ^ "The 2003 Bravewell Leadership Award – The Bravewell Collaborative". www.bravewell.org. Retrieved 2016-06-28.
  36. ^ "PMC.com : Archive". www.personalizedmedicinecoalition.org. Retrieved 2016-06-28.
  37. ^ "Chancellor Emeritus of Duke University's School of Medicine and Chairman, Proventys, Inc., Receives 2008 National IRI Medal | IRI". www.iriweb.org. Retrieved 2016-06-28.
  38. ^ "Frost & Sullivan Recognizes Excellence in Healthcare Innovation". www.frost.com. Retrieved 2016-06-16.
  39. ^ "NCABR Lauds 17 Life Science Leaders | North Carolina Biotech Center". www.ncbiotech.org. Retrieved 2016-06-28.
  40. ^ "2011 DukeMed Alumni awards to Wilson, Cohen & Snyderman | medicine.duke.edu". medicine.duke.edu. Retrieved 2016-06-28.
  41. ^ "Snyderman to Get NC Life Science Award | North Carolina Biotech Center". www.ncbiotech.org. Retrieved 2016-06-28.
  42. ^ "Ralph Snyderman Bio". Personalized Medicine World Conference 2016. Retrieved 2016-06-16.

External links[]

Retrieved from ""